A decade of tamoxifen reduces BCa recurrence

Article

Doubling the duration of adjuvant tamoxifen treatment in women estrogen receptor (ER)-positive breast cancer reduces risk of late recurrence and death compared with the current standard-of-care of 5 years' therapy. So say the results of a large international randomized trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium and simultaneously published in The Lancet.

Recent Videos
Radon exposure linked to increased risk of gestational diabetes | Image Credit: publichealth.columbia.edu.
Worse menopause symptom burden reported in rural women | Image Credit: uwmedicine.org.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Dr. Thomas outlines the future of the Safe Baby Safe Moms program | Image Credit: medstarhealth.org.
How the Safe Baby Safe Moms program transforms maternal and child health | Image Credit: medstarhealth.org.
ASCCP guidelines highlight critical information for extended HPV genotyping | Image Credit: linkedin.com.
Self-collection and extended genotyping advance cervical cancer screening | Image Credit: linkedin.com.
New trends in cervical cancer screening: Self-collection and barriers to adherence | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.